These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Management of Stage II testicular seminoma over a period of 40 years. Detti B; Livi L; Scoccianti S; Gacci M; Lapini A; Cai T; Meattini I; Mileo AM; Iannalfi A; Bruni A; Biti G Urol Oncol; 2009; 27(5):534-8. PubMed ID: 18848787 [TBL] [Abstract][Full Text] [Related]
25. The management of stage I nonseminomatous testicular germ cell tumors. Pectasides D; Farmakis D; Pectasides M Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698 [TBL] [Abstract][Full Text] [Related]
26. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800 [TBL] [Abstract][Full Text] [Related]
27. A decade of progress, current problems and future perspectives in testicular cancer. Javadpour N J Urol (Paris); 1985; 91(5):269-79. PubMed ID: 4078352 [TBL] [Abstract][Full Text] [Related]
28. Stage I nonseminomatous germ cell tumors: the case for management by risk stratification. Al Ghamdi AM; Jewett MA Can J Urol; 2005 Feb; 12 Suppl 1():62-5; discussion 103-4. PubMed ID: 15780169 [TBL] [Abstract][Full Text] [Related]
29. Management of clinical stage I nonseminomatous germ cell testicular cancer. Choueiri TK; Stephenson AJ; Gilligan T; Klein EA Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919 [TBL] [Abstract][Full Text] [Related]
30. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only. Ondrus D; Ondrusova M; Hornak M; Matoska J Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374 [TBL] [Abstract][Full Text] [Related]
32. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant treatment in the management of testis-confined germ cell tumours after orchidectomy. Sava T; Consoli F; Santo A; Cetto GL BJU Int; 2008 Jan; 101(2):155-9. PubMed ID: 17662077 [TBL] [Abstract][Full Text] [Related]
34. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer. Williams SB; Steele GS; Richie JP J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777 [TBL] [Abstract][Full Text] [Related]
35. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. Steiner H; Müller T; Gozzi C; Akkad T; Bartsch G; Berger AP BJU Int; 2006 Aug; 98(2):349-52. PubMed ID: 16626306 [TBL] [Abstract][Full Text] [Related]
36. Management of advanced germ-cell tumors of the testis. Fléchon A; Rivoire M; Droz JP Nat Clin Pract Urol; 2008 May; 5(5):262-76. PubMed ID: 18398406 [TBL] [Abstract][Full Text] [Related]
37. Controversies in the management of clinical stage I testis cancer. de Wit R; Fizazi K J Clin Oncol; 2006 Dec; 24(35):5482-92. PubMed ID: 17158533 [TBL] [Abstract][Full Text] [Related]
38. Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors. Gilbert DC; Van As NJ; Huddart RA Expert Rev Anticancer Ther; 2009 Feb; 9(2):223-33. PubMed ID: 19192960 [TBL] [Abstract][Full Text] [Related]
39. Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis. Link RE; Allaf ME; Pili R; Kavoussi LR J Clin Oncol; 2005 Aug; 23(24):5762-73. PubMed ID: 16110033 [TBL] [Abstract][Full Text] [Related]